Journal for ImmunoTherapy of Cancer

Top Research Topics at Journal for ImmunoTherapy of Cancer?

Cancer research, Immunotherapy, Immune system, Internal medicine and Oncology are the subjects of interest in Journal for ImmunoTherapy of Cancer. Journal for ImmunoTherapy of Cancer holds forums on Cancer research that merges themes from other disciplines such as T cell, Cytotoxic T cell and CD8, Antigen. Journal for ImmunoTherapy of Cancer features T cell research that overlaps with concepts in Cell biology.

The Immunotherapy study featured falls within the wider field of Cancer. Immune system studies tackled cover an aspect of the field of Immunology. The journal tackles issues in Immunology, particularly in the topics of Interleukin 21 and Antigen-presenting cell.

The studies in Internal medicine featured incorporate elements of Gastroenterology and Melanoma. In addition to Oncology research, Journal for ImmunoTherapy of Cancer aims to explore topics under Ipilimumab, Chemotherapy, Cohort and Clinical trial.

• Cancer research (41.37%)
• Immunotherapy (35.62%)
• Immune system (32.47%)

What are the most cited papers published in the journal?

• Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group (811 citations)
• Cytokine release syndrome (579 citations)
• Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. (520 citations)

Research areas of the most cited articles at Journal for ImmunoTherapy of Cancer:

The journal publications are mainly concerned with subjects like Immunotherapy, Internal medicine, Immune system, Cancer research and Oncology. The journal papers feature Immunotherapy research which is a component of studies in Cancer and Immunology. The journal papers hold forums on Cancer research that merge themes from other disciplines such as T cell, Chimeric antigen receptor, CD8, Antibody and Cytotoxic T cell.

What topics the last edition of the journal is best known for?

• Cancer
• Internal medicine
• Gene

The previous edition focused in particular on these issues:

The journal focuses largely on the fields of Immunotherapy, Cancer research, Immune system, Internal medicine and Tumor microenvironment. Journal for ImmunoTherapy of Cancer focuses on Immunotherapy but the discussions also offer insight into other areas such as Human leukocyte antigen and Melanoma. Topics in Cancer research explored in Journal for ImmunoTherapy of Cancer were investigated in conjunction with research in Immune checkpoint, T cell, CD8, Antigen and Cytotoxic T cell.

The concepts on Immune system presented in it can also apply to other research fields, including Tumor progression and Antibody. In the journal, Gastroenterology and Oncology are investigated in conjunction with one another to address concerns in Internal medicine research. The research on Tumor microenvironment tackled can also make contributions to studies in the areas of Cancer cell and In vivo.

The most cited articles from the last journal are:

• Targeting immunogenic cancer cell death by photodynamic therapy: past, present and future. (27 citations)
• HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy. (19 citations)
• Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1. (14 citations)

Papers citation over time

A key indicator for each journal is its effectiveness in reaching other researchers with the papers published at that venue.

The chart below presents the interquartile range (first quartile 25%, median 50% and third quartile 75%) of the number of citations of articles over time.

Top authors and change over time

The top authors publishing in Journal for ImmunoTherapy of Cancer (based on the number of publications) are:

• Jeffrey Schlom (55 papers) published 9 papers at the last edition, 4 less than at the previous edition,
• James L. Gulley (50 papers) published 8 papers at the last edition, 6 less than at the previous edition,
• Howard L. Kaufman (49 papers) absent at the last edition,
• Paolo A. Ascierto (46 papers) published 6 papers at the last edition, 14 less than at the previous edition,
• Thomas F. Gajewski (39 papers) published 2 papers at the last edition, 1 less than at the previous edition.

The overall trend for top authors publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top authors.

Top affiliations and change over time

Only papers with recognized affiliations are considered

The top affiliations publishing in Journal for ImmunoTherapy of Cancer (based on the number of publications) are:

• University of Texas MD Anderson Cancer Center (310 papers) published 44 papers at the last edition, 75 less than at the previous edition,
• Harvard University (230 papers) published 37 papers at the last edition, 54 less than at the previous edition,
• University of Pittsburgh (177 papers) published 20 papers at the last edition, 33 less than at the previous edition,
• National Institutes of Health (165 papers) published 23 papers at the last edition, 17 less than at the previous edition,
• Memorial Sloan Kettering Cancer Center (161 papers) published 23 papers at the last edition, 34 less than at the previous edition.

The overall trend for top affiliations publishing in this journal is outlined below. The chart shows the number of publications at each edition of the journal for top affiliations.

Publication chance based on affiliation

The publication chance index shows the ratio of articles published by the best research institutions in the journal edition to all articles published within that journal. The best research institutions were selected based on the largest number of articles published during all editions of the journal.

The chart below presents the percentage ratio of articles from top institutions (based on their ranking of total papers).Top affiliations were grouped by their rank into the following tiers: top 1-10, top 11-20, top 21-50, and top 51+. Only articles with a recognized affiliation are considered.

During the most recent 2021 edition, 8.97% of publications had an unrecognized affiliation. Out of the publications with recognized affiliations, 28.34% were posted by at least one author from the top 10 institutions publishing in the journal. Another 9.24% included authors affiliated with research institutions from the top 11-20 affiliations. Institutions from the 21-50 range included 11.70% of all publications and 50.72% were from other institutions.

Returning Authors Index

A very common phenomenon observed among researchers publishing scientific articles is the intentional selection of journals they have already attended in the past. In particular, it is worth analyzing the case when the authors participate in the same journal from year to year.

The Returning Authors Index presented below illustrates the ratio of authors who participated in both a given as well as the previous edition of the journal in relation to all participants in a given year.

Returning Institution Index

The graph below shows the Returning Institution Index, illustrating the ratio of institutions that participated in both a given and the previous edition of the conference in relation to all affiliations present in a given year.

The experience to innovation index

Our experience to innovation index was created to show a cross-section of the experience level of authors publishing in a journal. The index includes the authors publishing at the last edition of a journal, grouped by total number of publications throughout their academic career (P) and the total number of citations of these publications ever received (C).

The group intervals were selected empirically to best show the diversity of the authors' experiences, their labels were selected as a convenience, not as judgment. The authors were divided into the following groups:

• Novice - P < 5 or C < 25 (the number of publications less than 5 or the number of citations less than 25),
• Competent - P < 10 or C < 100 (the number of publications less than 10 or the number of citations less than 100),
• Experienced - P < 25 or C < 625 (the number of publications less than 25 or the number of citations less than 625),
• Master - P < 50 or C < 2500 (the number of publications less than 50 or the number of citations less than 2500),
• Star - P ≥ 50 and C ≥ 2500 (both the number of publications greater than 50 and the number of citations greater than 2500).

The chart below illustrates experience levels of first authors in cases of publications with multiple authors.